Eli Lilly & Co. and several other drugmakers plan to raise U.S. prices on certain medicines starting in January 2026.
The reported median price hike across the industry stands at approximately 4%. This increase aligns with the levels observed in 2025. These actions occur amid ongoing pressure from the Trump administration for drugmakers to reduce prices.
Simultaneously, Eli Lilly and partner Boehringer Ingelheim are cutting the price of their diabetes treatment, Jardiance. This specific reduction stems from negotiations with the U.S. government regarding the Medicare program.
Across the pharmaceutical sector, the overall number of planned price increases for 2026 exceeds the volume recorded at the same point in the previous year.